X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment. X. Long Zheng, MD, PhD: What are the unmet needs in acquired TTP [thrombotic thrombocytopenic purpura] ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) ...
cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...
Judicious use of caplacizumab (Cablivi) can reduce the risk of severe bleeding and help manage costs associated with the therapy in patients living with thrombotic thrombocytopenic purpura (TTP). The ...
License obtained from Kaketsuken is worldwide and exclusive except for Japan. Baxter International received a worldwide license to Kaketsuken’s drug candidate for the treatment of thrombotic ...
The fourth annual TTP Fair and Education Day, hosted by the lab of X. Long Zheng, M.D., Ph.D., Division Director, was held on Saturday, September 14, in Montgomery, Alabama at the Baptist Convention ...
The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).
A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback